Advancing Access to Cell and Gene Therapies in Medicaid-Reference-Cited by-同舟云学术

Advancing Access to Cell and Gene Therapies in Medicaid

Published:2024-06-18 Issue:23 Volume:331 Page:1989
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Kannarkat Joseph T.¹,Hernandez Inmaculada²,Parekh Natasha³

Affiliation:

1. School of Medicine, University of Maryland, Baltimore

2. Division of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, La Jolla

3. Marathon Health, Indianapolis, Indiana

Abstract

This Viewpoint presents the components of the payment model and the implementation challenges among the Center for Medicare and Medicaid Innovation, state Medicaid agencies, patients, and manufacturers.

Publisher

American Medical Association (AMA)

Link

https://jamanetwork.com/journals/jama/articlepdf/2819123/jama_kannarkat_2024_vp_240042_1717690916.55036.pdf

Reference7 articles.

1. Development of a severity classification system for sickle cell disease.;Shah;Clinicoecon Outcomes Res,2020

2. Examining misaligned incentives for payers and manufacturers in value-based pharmaceutical contracts.;Kannarkat;J Manag Care Spec Pharm,2020

3. Centers for Medicare & Medicaid Services. Cell and Gene Therapy Access Model. Published January 30, 2024. Accessed February 11, 2024. https://www.cms.gov/priorities/innovation/innovation-models/cgt

4. US Food and Drug Administration. FDA approves first gene therapies to treat patients with sickle cell disease. Published December 8, 2023. Accessed February 11, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease

5. Centers for Medicare & Medicaid Services. CGT Access Model frequently asked questions. Published January 30, 2024. Accessed February 11, 2024. https://www.cms.gov/cgt-access-model-frequently-asked-questions